22 patents
Utility
B7-H4 antibodies and methods of use thereof
14 Nov 23
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof.
Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
Filed: 10 Mar 20
Utility
Methods of treatment with CD80 extracellular domain polypeptides
17 Oct 23
This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.
Thomas Brennan, Barbara Sennino, Susannah D. Barbee, Ursula Jeffry
Filed: 27 Apr 18
Utility
Antibodies binding to VISTA at acidic pH
14 Mar 23
The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment.
Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
Filed: 13 Mar 18
Utility
Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
31 Jan 23
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Filed: 4 Mar 20
Utility
Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
24 Jan 23
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
Emma Masteller, Thomas Brennan, David Bellovin, Kevin P. Baker, Brian Wong
Filed: 10 Feb 20
Utility
FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
20 Sep 22
Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1.
Kristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
Filed: 22 Nov 16
Utility
Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
23 Aug 22
The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
Filed: 12 Sep 18
Utility
Antibodies binding to ILT4
2 Aug 22
The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses.
Xiao Min Schebye, Diana Yuhui Chen, Andrew Rankin, Xiaodi Deng, Joseph Toth, Linda Liang, Michelle Minhua Han, Christine Bee, Hong-An Truong, Mark J. Selby, Nils Lonberg, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Alan J. Korman
Filed: 9 Jul 19
Utility
B7-H4 antibodies and methods of use thereof
19 Apr 22
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof.
Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
Filed: 23 Aug 18
Utility
Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
19 Apr 22
Methods of identifying and using PSGL-1 antagonists are provided.
Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
Filed: 10 Jan 18
Utility
Afucosylated anti-FGFR2IIIB antibodies
1 Feb 22
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated.
Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
Filed: 6 Nov 18
Utility
Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
30 Nov 21
Antibodies that bind CSF1R are provided.
Justin Wong, Maximiliano Vasquez
Filed: 8 Jan 20
Utility
Anti-ROR1 antibodies
26 Oct 21
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer.
Brian Wong, Emma Masteller, Cheng Liu, Yiyang Xu, Hong Liu, Su Yan, Jingyi Xiang, Pei Wang
Filed: 17 May 16
Utility
CD80 extracellular domain polypeptides and their use in cancer treatment
24 Aug 21
This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
Filed: 15 Mar 19
Utility
Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
17 Aug 21
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
Filed: 15 May 18
Utility
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
13 Apr 21
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
Filed: 18 Jun 15
Utility
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
2 Nov 20
Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Brian Wong, Emma Masteller, Kris Reedquist
Filed: 23 Jan 19
Utility
NOPE for treatment of pathological muscle loss and weakness
12 Oct 20
Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
Filed: 23 Apr 17
Utility
Method of treating PVNS with anti-CSF1R antibodies
3 Aug 20
Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Robert Sikorski, Julie Hambleton, Nilacantan Sankar
Filed: 21 Jun 18
Utility
Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
13 Apr 20
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Filed: 8 Jan 19